Search

Corvus Pharmaceuticals Inc

Open

14.31 -3.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.67

Max

15.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+100.27% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

61M

1.2B

Vorheriger Eröffnungskurs

18.01

Vorheriger Schlusskurs

14.31

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Aug. 2026, 23:56 UTC

Fluence Energy Inc shares are higher in after-market trading. Broader market context includes recent PCE price index data indicating ongoing inflationary pressures.

26. Aug. 2026, 23:56 UTC

Correlated Moves
Social Media

Tesla shares are trading higher in after-market hours, supported by increased institutional holdings from major investors and a broader market uptick.

26. Aug. 2026, 23:56 UTC

Shares of Stanley Black & Decker Inc rose modestly in after-market trading, settling at a cumulative return of 0.33% since Wednesday's close.

26. Aug. 2026, 23:56 UTC

Shares of Synchrony Financial are lower in after-market trading, moving from an early high to a low during the session.

26. Aug. 2026, 23:56 UTC

RTX Corp. shares are trading lower in after-market hours, with significant volatility noted since Wednesday's close and prices below the 20-day moving average.

26. Aug. 2026, 23:56 UTC

Macro Event

EUR/AUD trades lower as Australia's July inflation rate declines to 3.5%, exceeding expectations. The currency pair remains near the lower end of its one-month range.

26. Aug. 2026, 23:56 UTC

Ralph Lauren Corp shares are lower in after-market hours, continuing a trend from regular trading. The stock remains below its 20-day moving average.

26. Aug. 2026, 23:56 UTC

News

Constellation Brands reported first-quarter results that beat expectations, driven by beer sales. The company also reaffirmed EPS guidance and plans a $100 million investment.

26. Aug. 2026, 23:56 UTC

Cheniere Energy shares are trading lower in after-market hours. No specific news was identified to explain this price movement.

26. Aug. 2026, 23:52 UTC

AT&T Inc shares are lower in after-market hours with no specific news identified. Broader market data on rising consumer prices may influence investor sentiment.

26. Aug. 2026, 23:52 UTC

MARA Holdings Inc. shares are higher in after-market hours, supported by robust economic data and easing crude oil prices, reflecting a positive market trend.

26. Aug. 2026, 23:52 UTC

Correlated Moves

The SGD/CHF is trading higher, supported by a recent rise in USD/CHF. It remains near the upper end of its one-month trading range.

26. Aug. 2026, 23:52 UTC

The Swiss franc is trading lower against the South African rand during Wednesday's session, remaining near the lower end of its one-month range.

26. Aug. 2026, 23:51 UTC

The Nikkei 225 Index is trading higher in after-market hours, continuing a trend of upward movement following Wednesday's close.

26. Aug. 2026, 23:51 UTC

Ladder Capital Corp shares are higher in after-market trading, moving up from earlier lows and trading above its 20-day moving average. No specific news identified.

26. Aug. 2026, 23:51 UTC

Correlated Moves

Alpha and Omega Semiconductor rises in after-hours trading, recovering from an earlier dip. The stock advanced sharply since Wednesday's close, tracking semiconductor sector gains.

26. Aug. 2026, 23:51 UTC

Correlated Moves

PagerDuty Inc. shares are higher in after-market hours, driven by strong overall market momentum and Salesforce Inc.'s significant gain. Positive economic data supports this trend.

26. Aug. 2026, 23:51 UTC

Cabaletta Bio Inc shares are lower in after-market trading, following a decline earlier in the session. No specific news was identified to explain the movement.

26. Aug. 2026, 23:51 UTC

JetBlue Airways Corp shares are higher in after-market trading, reflecting broader market gains amid positive economic data on consumer prices and durable goods orders.

26. Aug. 2026, 23:51 UTC

Community Financial System Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

26. Aug. 2026, 23:51 UTC

Beam Therapeutics Inc shares are higher in after-market hours, reflecting a broadly positive market trend. The stock is near the upper end of its one-month range.

26. Aug. 2026, 23:51 UTC

Arbor Realty Trust is trading higher in after-market hours, advancing from Wednesday's close. Shares earlier pulled back but remain above the prior close.

26. Aug. 2026, 23:51 UTC

Yelp Inc shares are higher in after-market trading, recovering from an earlier dip. The stock remains below its 20-day moving average.

26. Aug. 2026, 23:51 UTC

PENN Entertainment Inc. shares rose in after-market trading, gaining modestly since Wednesday's close despite remaining below its 20-day moving average.

26. Aug. 2026, 23:51 UTC

U.S. markets gain momentum as inflation data reveals slight consumer price rise, while UK car production declines and copper prices surge amid strong demand.

26. Aug. 2026, 23:51 UTC

U.S. equity indices rise amid positive global sentiment and inflation data, while investors await Nvidia earnings and navigate geopolitical tensions affecting oil prices.

26. Aug. 2026, 23:51 UTC

Asia equity markets rise on falling crude oil prices and tech stock gains, while caution prevails ahead of U.S. inflation data and Fed Chair's speech.

26. Aug. 2026, 23:51 UTC

Mixed trading in European equities as easing inflation concerns clash with rising energy prices and UK economic woes.

26. Aug. 2026, 23:51 UTC

Brazil's Q2 GDP Growth Rate Expected to Rise by 0.8% Amidst Global Economic Challenges, Following a Strong 1.1% Expansion in Q1

26. Aug. 2026, 23:51 UTC

Market Cautiously Awaits Insights from Jackson Hole Symposium as Inflation Concerns and Fed Dissent Shape Economic Outlook.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

100.27% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  100.27%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat